K&L Gates Advises Rocket Pharmaceuticals on $189.8 Million Public Offering
Rocket Pharmaceuticals Raises $194.8 Million in Public Offering and Private Placement
New York, NY – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a biotechnology company focused on developing genetic therapies for rare diseases, announced the triumphant completion of a public offering and concurrent private placement, raising a total of $194.8 million.
The public offering, led by Morgan Stanley, Leerink Partners, and Cantor, saw the sale of 15,180,000 shares of Rocket’s common stock at a price of $12.50 per share, generating $189.8 million in proceeds.
In a concurrent move, Rocket also secured $5.0 million through a private placement of pre-funded warrants to purchase 400,000 shares of common stock at an offering price of $12.49 per pre-funded warrant. LifeSci Capital acted as led manager for this placement.
“This successful financing will allow us to advance our pipeline of potentially life-changing therapies for patients with rare diseases,” said [Insert Quote from Rocket Pharmaceuticals CEO or relevant executive].”We are grateful for the strong support from investors who share our vision.”
Global law firm K&L Gates LLP provided legal counsel to Rocket pharmaceuticals in both transactions. The K&L Gates team was led by New York partner Whitney Smith and Charlotte partner Sean Jones, with significant contributions from a team of experienced attorneys across multiple offices.”we are proud to have supported Rocket Pharmaceuticals in this important milestone,” said Whitney Smith. “Their innovative work in the field of genetic therapies holds immense promise for patients in need.”
K&L Gates’ Corporate practice, with its global reach and deep expertise in capital markets transactions, played a crucial role in guiding Rocket Pharmaceuticals through the complexities of the offering and private placement.
This financing positions Rocket Pharmaceuticals to continue its mission of developing groundbreaking treatments for rare diseases, offering hope to patients and their families.
Rocket Pharmaceuticals Secures $194.8 Million to Advance Rare Disease Therapies
New York, NY – Rocket Pharmaceuticals, a leading biotechnology company focused on genetic therapies for rare diseases, announced the prosperous completion of a public offering and concurrent private placement, raising a total of $194.8 million.
“This successful financing will allow us to advance our pipeline of potentially life-changing therapies for patients with rare diseases,” said [Insert Quote from Rocket Pharmaceuticals CEO or relevant executive]. “We are grateful for the strong support from investors who share our vision.”
The public offering, led by Morgan Stanley, Leerink Partners, and Cantor, saw the sale of 15,180,000 shares of Rocket’s common stock at $12.50 per share, generating $189.8 million. A concurrent private placement of pre-funded warrants to purchase 400,000 shares of common stock at $12.49 per pre-funded warrant, led by LifeSci Capital, raised an additional $5 million.
Global law firm K&L Gates LLP served as legal counsel to Rocket Pharmaceuticals in both transactions. The firm’s team, led by New York partner Whitney Smith and Charlotte partner Sean Jones, provided essential guidance throughout the process.
“We are proud to have supported Rocket Pharmaceuticals in this critically important milestone,” said Whitney smith. “Their innovative work in the field of genetic therapies holds immense promise for patients in need.”
This important financing empowers Rocket Pharmaceuticals to continue its critical mission of developing groundbreaking treatments for rare diseases, bringing hope to patients and their families worldwide.